<Of course the other way to view small cap biotechs is as non-expiring options on the potential success the pipeline. So maybe from that perspective dilution is the price you pay for having your option not expire.>
Agreed - and as credit tightens, pipe deals become more expensive - bigger discounts from market and more favorable warrant deals, resulting in greater dilution.
Market Data 
Markets 
AI
